Abstract:Background Candida species are commonly detected as colonizers of the oral cavity; candidiasis or candidemia can develop in patients who are immunocompromised. Use of topical or inhaled glucocorticoids can alter the spectrum of Candida species and can promote oral candidiasis. The present study aims to evaluate the diversity of Candida species in the oral cavity and their susceptibility to antifungal agents in patients undergoing treatment with systemic glucocorticoids (SGCs) compared with non-users. Methods We conducted a descriptive, analytical, cross-sectional study that enrolled 120 patients with oral problems who were undergoing treatment with SGCs and who were admitted to the hospital of the First Affiliated Hospital, College of Medicine, Zhejiang University and Zhejiang Hospital, Hangzhou, China, between February 2019 and September 2019. One hundred and twenty age-and sex-matched patients were recruited as the SGC non-user control group. Demographic data included oral complaints and underlying diseases; symptoms of oral candidiasis were identified on physical examination. Candida species were collected using a concentrated oral rinse. Identification of fungal isolates was based on conventional phenotypic methods assisted by DNA sequence analysis of the internal transcribed spacer (ITS) rDNA gene region. Antifungal activities of anidulafungin, amphotericin B, micafungin, caspofungin, 5-flucytosine, posaconazole, voriconazole, itraconazole, and fluconazole were evaluated using the Sensititre YeastOneTM YO10 panel supplemented by the CLSI-M27-A3 protocol. Results Fifty-two (43.33%) out of the 120 patients undergoing with SGCs were diagnosed with oral candidiasis, compared with 14 (11.67%) of the non-users (P < 0.05). Likewise, we collected 88 strains from 73.33% of the SGC users compared with only 48 (40%) from non-users (P < 0.05). Candida albicans was detected most frequently in both groups (45.45% vs 66.67%, respectively; P = 0.033); the overall frequency of non-Candida albicans (NCA) strains isolated from patients treated with SGCs were significantly higher than that identified among non-users (51.14% vs 33.33%, respectively; P = 0.046), although there were no significant differences concerning any single species of NCA. Resistance of C. albicans to itraconazole (P = 0.004) and fluconazole (P = 0.001) was significantly higher in patients treated with SGCs than in non-users; however, echinocandins, amphotericin B, voriconazole, and posaconazole were all active against strains from both participant groups with no significant differences detected. Conclusion Taken together, our findings indicate that SGC therapy may result in an increased prevalence of oral candidiasis as reflected by the clinical presentations and strains isolated; these findings were also associated with an increased frequency of NCA strains. SGC therapy was also associated with an increased frequency of C. albicans strains that were resistant to both itraconazole and fluconazole. The impact of SGC therapy on Candida species in the oral cavity requires further study.

Genetic diversity in Fluconazole-resistant and -susceptible oral Candida albicans isolated from patients with Sjgren's syndrome

Oral Prevalence of Candida Species in Patients Undergoing Systemic Glucocorticoid Therapy and the Antifungal Sensitivity of the Isolates

Multiple OralCandidaInfections in Patients with Sjögren’s Syndrome — Prevalence and Clinical and Drug Susceptibility Profiles

Study of Azole Resistant Mechanisms of Candida albicans

Genotyping and Antifungal Susceptibility of Candida Albicans Isolates from AIDS Patients

Antifungal Susceptibility and Genotypes of Candida Albicans Strains from Patients with Vulvovaginal Candidiasis

Multiple oral Candida infections in patients with Sjogren's syndrome -- prevalence and clinical and drug susceptibility profiles.

Parallel evolution of fluconazole resistance and tolerance in Candida glabrata

[Antifungal Susceptibility Test of Genotypes of Candida Albicans from Patients with Atrophic or Erosive Oral Lichen Planus].

Genetic relatedness among azole-resistant Candida tropicalis clinical strains in Taiwan from 2014 to 2018

Correlation Between Azole Susceptibilities, Genotypes, and ERG11 Mutations in Candida Albicans Isolates Associated with Vulvovaginal Candidiasis in China

Resistant Mechanisms of Candida albicans to Azoles

Comparison of Two Molecular Typing Methods to Assess Genetic Relatedness of Fluconazole-resistant Candida Albicans

Susceptibility of non-Candida albicans isolates to common antifungal agents

[Molecular Mechanisms of Fluconazole Resistance in Clinical Isolates of Candida Glabrata].

[25S Rdna Genotype and Antifungal Susceptibility of Vaginal Candida Albicans].

Species distribution and antifungal susceptibility of Candida sp. isolates from AIDS patients with oropharyngeal candidiasis

Genomic description of acquired fluconazole- and echinocandin-resistance in patients with serial Candida glabrata isolates

Multilocus Sequence Typing Analysis of Candida Africana from Vulvovaginal Candidiasis

Emergence of Antifungal Resistant Subclades in the Global Predominant Phylogenetic Population of Candida Albicans.

ERG11 mutations and expression of resistance genes in fluconazole-resistant Candida albicans isolates